「gefitinib」に関連した動画の一覧

	Gefitinib appropriate first-line agent for certain lung cancers  NEW YORK (Reuters Health) -- Results of a meta-analysis confirm that the oral tyrosine kinase inhibitor gefitinib is effective as first-line therapy in patients with advanced non-small-cell lung cancer whose tumors harbor EGFR (epidermal growth factor receptor) mutations. For more information, please visit: www.thedoctorschannel.com 2011年06月23日再生回数 422
	Dr. West on the Gefitinib Advanced NSCLC Trial  H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses findings from a phase III, randomized, multicenter, parallel group study (NCT00770588) that examined the efficacy of gefitinib as a maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC). The trial discovered that progression free survival was much longer in Chinese patients receiving gefitinib than those receiving placebo. 2011年07月20日再生回数 111
	Geftinat Natco, Geftinat India, Gefitinib Iressa 250mg Tablets Buy Online  www.way2rx.com Geftinat 250mg tablets, Generic Iressa, gefitinib 250mg world wide delivery available only at www.way2rx.com 2010年07月11日再生回数 354
	Iressa  Iressa - link to online store freshmedicines.com Serophene (Clomid) 25mg / 50mg / 100mg Clomid is often used in the treatment of polycystic ovarian syndrome (PCOS) related infertility. Magnificent quality of Clomid - Clomiphene iressa buy in uk iressa price usa iressa review nz iressa... 2012年02月06日再生回数 358
	Mechanism of Iressa Drug Resistance  3D version found at: www.youtube.com Protein kinases are a group of enzymes that transfer a phosphate from a molecule, such as the cofactor ATP, to one or more amino acid residues in a signaling protein. Over-functioning results in uncontrollable growth of cells, a tumor formation. ATP binds in the ATP-binding site of the tyrosine kinase domain and makes 2 important hydrogen bonds to the protein. A threonine side-chain at position 790 is present in the binding interaction. The binding of ATP to the tyrosine kinase domain of the protein leads to phosphorylation of the tyrosine residue, and as a result, proliferation of cells. The drug Iressa or Gefitinib is a Tyrosine Kinase inhibitor that blocks the binding of ATP, and thus no phosphorylation. Although it is similar in size, Iressa does not resemble the structure of the ATP molecule, but the drug binds in the ATP-binding pocket and prevents the protein from phosphorylation. The higher concentration of Iressa as compared to ATP allows the drug to prevent ATP from binding. The crucial binding region for Iressa is at the side chain of the amino acid Threonine at position 790. This binding prevents the endogenous ATP molecule from binding to the tyrosine kinase domain. The protein has shown that it can become resistant to Iressa by mutation of an amino acid. Threonine, at position 790 where Iressa binds is mutated to Methionine.. Because the water molecule is no longer close to Iressa after the amino acid mutation, the ... 2012年01月14日再生回数 720
	EMCTO 2011: Targeted maintenance therapies for advanced non-small cell lung cancer  Dr Cesare Gridelli,SG Moscati Hospital, Avellino, Italy, talks about maintenance treatment with targeted therapies for EGFR mutated non-small cell lung cancer patients and discusses a number of drugs which could potentially be effective maintenance treatments. These drugs include the TKI inhibitors erlotinib and gefitinib, the monoclonal antibody cetuximab and and VEGFR inhibitors such as bevacizumab. Dr Gridelli talks about the toxicity profiles and explains how the most effective treatment will vary depending on the patient. 2011年03月15日再生回数 238
	GRACEcast-068_Lung-Cancer_Sequist on Acquired Resistance to EGFR  cancergrace.org Dr. Lecia Sequist of Massachusetts General Hospital presents a summary of the challenge of acquired resistance to EGFR tyrosine kinase inhibitors like Tarceva (erlotinib) and Iressa (gefitinib), along with emerging ideas for overcoming it. 2011年07月26日再生回数 202
	Dr. Scagliotti Discusses EGFR Mutations in NSCLC  Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, explains that the identification of epidermal growth factor receptor (EGFR) mutations in the subset of non-small cell lung cancer (NSCLC) has greatly changed the survival expectations in stage IV NSCLC. Scagliotti discusses the benefit patients receive simply by taking one pill a day, gefitinib or erlotinib, both tyrosine kinase inhibitors. This benefit has been established using multiple trials that looked at several demographic factors. These trials have showed an increase in the progression free survival of patients receiving EGFR-TKIs. 2011年09月17日再生回数 140
	iMolview  For more information: www.molsoft.com iMolview is an app for the iPhone and iPad that lets you browse protein, DNA, and drug molecules in 3D. The app has a direct link to the Protein Data Bank (PDB) and DrugBank and has a fast and easy to use interface. Touching the molecules via the screen allows you to interact immediately with the 3D structures in a unique way. You can zoom in and out, rotate, spin, pan, and clip the 3D molecules with your finger tips in ways that are impossible using a traditional mouse and desktop computer. iMolView allows you to search for drugs such as 'ibuprofen' or 'gefitinib' in DrugBank, or proteins like 'insulin' or 'thyroid receptor' in the PDB and immediately explore their structure and annotation. This handy app allows you to quickly and easily view and interact with 3D molecules anywhere and at any time whether you are at the bench, at a conference, or just having coffee with colleagues! 2011年05月13日再生回数 1708
	Dr. Scagliotti on EGFR Targeted Therapy Survival Benefits  Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, stresses the importance of testing and treating non-small cell lung cancer (NSCLC) patients based on the epidermal growth factor receptor (EGFR) mutation. The average survival benefit experienced by NSCLC patients treated with the EGFR targeted therapies erlotinib and gefitinib, in either the first or second-line, was around 24 months. Scagliotti explains that before the use of the EGFR-mutation in NSCLC it was impossible to achieve this type of survival benefit. 2011年09月28日再生回数 49